Search research articles
Contact Us
Filters
Showing results (11-20 of 49) with videos related to
Page
of 5
Sort By:
Dermatology and Therapy
|
December 18, 2020
Two-Year US Pharmacovigilance Report on Brodalumab
Mark Lebwohl, Craig Leonardi, Jashin J Wu, et al.
Journal of Drugs in Dermatology : JDD
|
August 27, 2020
One-Year Pharmacovigilance Update of Brodalumab
Mark Lebwohl, Craig Leonardi, Jashin J Wu, et al.
Journal of Drugs in Dermatology : JDD
|
August 3, 2007
Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris
Joel Schlessinger, Alan Menter, Michael Gold, et al.
Dermatology and Therapy
|
May 28, 2021
Psoriasis Severity Assessment Combining Physician and Patient Reported Outcomes: The Optimal Psoriasis Assessment Tool
Craig Leonardi, Kyoungah See, Gaia Gallo, et al.
BMC Dermatology
|
February 28, 2007
Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series
Michelle A Lowes, Francesca Chamian, Maria V Abello, et al.
The New England Journal of Medicine
|
March 30, 2012
Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis
Craig Leonardi, Robert Matheson, Claus Zachariae, et al.
Journal of Drugs in Dermatology : JDD
|
August 19, 2016
The Aerosol Foam Formulation of the Fixed Combination Calcipotriene Plus Betamethasone Dipropionate Improves the Health-Related Quality of Life in Patients With Psoriasis Vulgaris: Results from the Randomized PSO-FAST Study
Craig Leonardi, Jerry Bagel, Paul Yamauchi, et al.
Journal of Drugs in Dermatology : JDD
|
December 15, 2015
Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST)
Craig Leonardi, Jerry Bagel, Paul Yamauchi, et al.
Journal of Medical Economics
|
August 2, 2017
Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis
Sarah Al Sawah, Shonda A Foster, Russel Burge, et al.
American Journal of Clinical Dermatology
|
August 13, 2011
The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials
Craig Leonardi, Kim Papp, Bruce Strober, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 49) with videos related to
Sort By:
Page
of 5
Dermatology and Therapy
|
December 18, 2020
Two-Year US Pharmacovigilance Report on Brodalumab
Mark Lebwohl, Craig Leonardi, Jashin J Wu, et al.
Journal of Drugs in Dermatology : JDD
|
August 27, 2020
One-Year Pharmacovigilance Update of Brodalumab
Mark Lebwohl, Craig Leonardi, Jashin J Wu, et al.
Journal of Drugs in Dermatology : JDD
|
August 3, 2007
Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris
Joel Schlessinger, Alan Menter, Michael Gold, et al.
Dermatology and Therapy
|
May 28, 2021
Psoriasis Severity Assessment Combining Physician and Patient Reported Outcomes: The Optimal Psoriasis Assessment Tool
Craig Leonardi, Kyoungah See, Gaia Gallo, et al.
BMC Dermatology
|
February 28, 2007
Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series
Michelle A Lowes, Francesca Chamian, Maria V Abello, et al.
The New England Journal of Medicine
|
March 30, 2012
Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis
Craig Leonardi, Robert Matheson, Claus Zachariae, et al.
Journal of Drugs in Dermatology : JDD
|
August 19, 2016
The Aerosol Foam Formulation of the Fixed Combination Calcipotriene Plus Betamethasone Dipropionate Improves the Health-Related Quality of Life in Patients With Psoriasis Vulgaris: Results from the Randomized PSO-FAST Study
Craig Leonardi, Jerry Bagel, Paul Yamauchi, et al.
Journal of Drugs in Dermatology : JDD
|
December 15, 2015
Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST)
Craig Leonardi, Jerry Bagel, Paul Yamauchi, et al.
Journal of Medical Economics
|
August 2, 2017
Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis
Sarah Al Sawah, Shonda A Foster, Russel Burge, et al.
American Journal of Clinical Dermatology
|
August 13, 2011
The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials
Craig Leonardi, Kim Papp, Bruce Strober, et al.
Page
of 5